Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).

NCT06087536 is registered in ClinicalTrials.gov with Omnix Medical Ltd as lead sponsor.

NCT NCT06087536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06087536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
Lead sponsor
Omnix Medical Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2026
Completion date
March 31, 2027
Enrollment
54 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia